FIRMAGON 120 mg powder and solvent for solution for injection

DRUG4 trials

Sponsors

Turku University Central Hospital, Ziekenhuis Aan De Stroom, UZ Leuven, Friedrich-Schiller-Universitaet Jena

Conditions

Oligorecurrent hormone-sensitive prostate cancer patientsProstate cancerbenign prostate hyperplasiaprostate cancer

Phase 2

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

RecruitingCTIS2022-501551-90-00

Ziekenhuis Aan De StroomProstate cancer

Start: 2023-12-13Target: 583Updated: 2026-01-23

Phase 3

Metastasis-directed therapy for oligorecurrent prostate cancer : A randomized phase III trial.

RecruitingCTIS2022-502373-42-00

UZ LeuvenOligorecurrent hormone-sensitive prostate cancer patients

Start: 2022-04-25Target: 873Updated: 2025-03-31

A randomised, phase 3 trial comparing 3-weekly docetaxel 75 mg/m2 (in a 3 week cycle) versus 2-weekly Docetaxel 50 mg/m2 (in a 4 week cycle) in combination with Darolutamide + ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC)

Active, not recruitingCTIS2022-502634-52-00

Friedrich-Schiller-Universitaet Jenaprostate cancer

Start: 2023-05-16Target: 280Updated: 2025-08-25

Phase 4

Prostate medication, metabolism and gut microbiota, PROMED.

RecruitingCTIS2022-500618-24-00

Turku University Central Hospitalbenign prostate hyperplasia, prostate cancer

Start: 2022-12-01Target: 100Updated: 2022-10-04